Kymera Therapeutics Dirección
Dirección controles de criterios 2/4
El CEO de Kymera Therapeutics' es Nello Mainolfi , nombrado en Jun 2019, tiene una permanencia de 4.83 años. compensación anual total es $6.93M, compuesta por 8.7% salario y 91.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.01% de las acciones de la empresa, por valor de $21.14M. La antigüedad media del equipo directivo y de la junta directiva es de 2.9 años y 3.6 años, respectivamente.
Información clave
Nello Mainolfi
Chief Executive Officer (CEO)
US$9.7m
Compensación total
| Porcentaje del salario del CEO | 6.6% |
| Permanencia del CEO | 4.9yrs |
| Participación del CEO | 1.0% |
| Permanencia media de la dirección | 3yrs |
| Promedio de permanencia en la Junta Directiva | 3.7yrs |
Actualizaciones recientes de la dirección
Recent updates
We Think Kymera Therapeutics (NASDAQ:KYMR) Can Easily Afford To Drive Business Growth
May 03
Kymera Therapeutics: Advancing Into Phase 2 With Partner Sanofi - I Still Have Faith
Mar 21Kymera Therapeutics, Inc. (NASDAQ:KYMR) Released Earnings Last Week And Analysts Lifted Their Price Target To US$47.43
Feb 25Optimistic Investors Push Kymera Therapeutics, Inc. (NASDAQ:KYMR) Shares Up 39% But Growth Is Lacking
Feb 17Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shares Climb 33% But Its Business Is Yet to Catch Up
Dec 29We Think Kymera Therapeutics (NASDAQ:KYMR) Needs To Drive Business Growth Carefully
Nov 06Industry Analysts Just Made A Substantial Upgrade To Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Revenue Forecasts
Aug 31Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Aug 04Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Share Price Not Quite Adding Up
May 21We're Hopeful That Kymera Therapeutics (NASDAQ:KYMR) Will Use Its Cash Wisely
Apr 16Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth
Dec 28Kymera KT-333 gets FDA orphan drug status for blood cancer subtype
Sep 15Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces
Aug 15Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M
Aug 09Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation
Jul 04Kymera Therapeutics: A First Take
Feb 28Companies Like Kymera Therapeutics (NASDAQ:KYMR) Can Afford To Invest In Growth
Feb 28Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -US$155m |
| Dec 31 2023 | US$10m | US$640k | -US$147m |
| Sep 30 2023 | n/a | n/a | -US$167m |
| Jun 30 2023 | n/a | n/a | -US$158m |
| Mar 31 2023 | n/a | n/a | -US$159m |
| Dec 31 2022 | US$7m | US$600k | -US$155m |
| Sep 30 2022 | n/a | n/a | -US$154m |
| Jun 30 2022 | n/a | n/a | -US$139m |
| Mar 31 2022 | n/a | n/a | -US$124m |
| Dec 31 2021 | US$12m | US$571k | -US$100m |
| Sep 30 2021 | n/a | n/a | -US$79m |
| Jun 30 2021 | n/a | n/a | -US$58m |
| Mar 31 2021 | n/a | n/a | -US$48m |
| Dec 31 2020 | US$4m | US$454k | -US$55m |
| Sep 30 2020 | n/a | n/a | -US$53m |
| Jun 30 2020 | n/a | n/a | -US$57m |
| Mar 31 2020 | n/a | n/a | -US$52m |
| Dec 31 2019 | US$2m | US$362k | -US$41m |
Compensación vs. Mercado: La compensación total de Nello($USD9.67M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD5.61M).
Compensación vs. Ingresos: La compensación de Nello ha aumentado mientras la empresa no es rentable.
CEO
Nello Mainolfi (44 yo)
4.9yrs
Permanencia
US$9,670,542
Compensación
Dr. Nello Mainolfi, M.D., Ph D., is Co-Founder, President, Chief Executive Officer and Director at Kymera Therapeutics, Inc. since November 2019. Previously, at Kymera Therapeutics, Dr. Mainolfi served as...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 8.7yrs | US$266.46k | 0% $ 0 | |
| Co-Founder | 4.9yrs | US$9.67m | 1% $ 22.3m | |
| Chief Financial Officer | 4.8yrs | US$4.16m | 0.15% $ 3.3m | |
| Chief Operating Officer | less than a year | US$5.46m | 0% $ 0 | |
| Chief Legal Officer & Corporate Secretary | 1.3yrs | US$4.97m | 0.0099% $ 220.4k | |
| Chief Medical Officer | 5.7yrs | US$3.47m | 0.089% $ 2.0m | |
| Head of People & Culture | 2yrs | sin datos | sin datos | |
| Head of Research | 3yrs | sin datos | sin datos |
3.0yrs
Permanencia media
58yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de KYMR se considera experimentado (2.9 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| Co-Founder & Independent Chairman | 8.7yrs | US$266.46k | 0% $ 0 | |
| Co-Founder | 4.5yrs | US$9.67m | 1% $ 22.3m | |
| Independent Director | 2.3yrs | US$236.46k | 0% $ 0 | |
| Independent Director | 6yrs | US$243.96k | 0% $ 0 | |
| Lead Independent Director | less than a year | sin datos | sin datos | |
| Independent Director | 3.2yrs | US$246.46k | 0% $ 0 | |
| Independent Indepednet Director | 1.8yrs | US$246.46k | 0% $ 0 | |
| Independent Director | 3.8yrs | US$241.46k | 0% $ 0 | |
| Independent Director | 3.7yrs | US$243.96k | 0% $ 0 | |
| Independent Director | 1.5yrs | US$231.46k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$236.46k | 0% $ 0 |
3.7yrs
Permanencia media
52yo
Promedio de edad
Junta con experiencia: La junta directiva de KYMR se considera experimentada (3.6 años de antigüedad promedio).